0000000000512787

AUTHOR

ŁUkasz Matusiak

0000-0003-2067-4929

showing 3 related works from this author

Quality-of-Life Impairment among Patients with Hidradenitis Suppurativa: A Cross-Sectional Study of 1795 Patients

2021

The chronic, inflammatory skin disorder hidradenitis suppurativa (HS) is associated well documented negative influences on patients&rsquo

medicine.medical_specialtyCross-sectional studyPopulationDiseaseDemographic dataArticleGeneral Biochemistry Genetics and Molecular Biology030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineQuality of lifeInternal medicineMedicineHidradenitis suppurativa030212 general & internal medicineDLQIlcsh:ScienceeducationEcology Evolution Behavior and Systematicseducation.field_of_studyintegumentary systembusiness.industryhidradenitis suppurativaPaleontologyDermatology Life Quality Indexmedicine.diseasehumanitiesquality of lifeSpace and Planetary ScienceCohortlcsh:QbusinessLife
researchProduct

LAight® Therapy Significantly Enhances Treatment Efficacy of 16 Weeks of Topical Clindamycin Solution in Hurley I and II Hidradenitis Suppurativa: Re…

2021

<b><i>Background:</i></b> Hidradenitis suppurativa (HS) is a chronic, inflammatory, burdensome skin disease where medical first-line treatment is still limited to long-term, topical and/or systemic antibiotics. The RELIEVE study aimed at evaluating the efficacy of LAight® therapy – a combination of intense pulsed light and radiofrequency – as an adjunct treatment to first-line therapies in Hurley stage I and II HS. <b><i>Methods:</i></b> The RELIEVE study was performed as a two-period multicenter randomized controlled trial with blinded assessment. For period A from week 0 to week 16, the 88 participating subjects were randomized into either a…

medicine.medical_specialtymedicine.medical_treatmentDermatologyIntense pulsed lightSeverity of Illness Indexlaw.inventionRandomized controlled trialQuality of lifelawInternal medicineClinical endpointMedicineHumansHidradenitis suppurativabusiness.industryClindamycinClindamycinmedicine.diseaseTreatment efficacyAnti-Bacterial AgentsHidradenitis SuppurativaTreatment OutcomeTopical clindamycinChronic DiseaseQuality of Lifebusinessmedicine.drugDermatology (Basel, Switzerland)
researchProduct

Itch in the era of COVID‐19 pandemic: An unfolding scenario

2020

Abstract Coronavirus disease 2019 (COVID‐19) is an infectious disease, caused by severe acute respiratory syndrome (SARS)‐CoV‐2, that broke out in December 2019. In just 4 months it has spread to almost every country in the world and up to April 18, 2020, the virus has infected more than two million people. Itch is the most common symptom in dermatology and a frequent one of systemic diseases. The association of itch and viral diseases has been widely documented; however, the actual prevalence of itch in the patients suffering from new the SARS‐CoV‐2 infection is still unknown. In this paper, we present a review of the available literature on the topic of itch in the affected population. Mo…

Special Issue Articlesmedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)PopulationDermatologyViral infectionVirus030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineCOVID‐19PandemicHumansMedicineskin and connective tissue diseaseseducationPersonal Protective Equipmenteducation.field_of_studySARS-CoV-2business.industryPruritusCOVID-19Special Issue ArticleGeneral MedicineDermatologyInfectious disease (medical specialty)030220 oncology & carcinogenesisPsychosocial stressbusinessStress PsychologicalDermatologic Therapy
researchProduct